FDA approves additional indication for Evarrest (fibrin sealant patch) for bleeding control during liver surgery-Ethicon

The FDA has approved an additional indication for Ethicon's Evarrest (fibrin sealant patch), as an adjunct to hemostasis for control of bleeding during adult liver surgery. Clinical studies demonstrate that Evarrest is greater than 94 percent effective in controlling bleeding across challenging patient types and surgical situations, compared to current standard of care (less than 53 percent).

Evarrest provides a rapid, predictable solution for problematic bleeding, minimizing surgical procedure disruption. Evarrest has been shown to deliver a cost savings compared with current standard of care, when taking into account hemostat cost, OR time, transfusion requirements and retreatment. The low rate of re-bleeding with Evarrest reduces the need for other hemostatic therapies.